Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
My Watchlist
Top Indices
My Portfolio

Biodesix, Inc. - Common Stock (NQ:BDSX)

0.6277 +0.0216 (+3.56%)
Streaming Delayed Price Updated: 4:00 PM EDT, Apr 2, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Biodesix, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9 Next >
12 Health Care Stocks Moving In Wednesday's After-Market Session
Via Benzinga
12 Health Care Stocks Moving In Tuesday's After-Market Session
Via Benzinga
12 Health Care Stocks Moving In Friday's After-Market Session
Via Benzinga
Top movers in Tuesday's after hours session
Wondering what's happening in today's after-hours session? Stay tuned for the latest updates on stock movements. 
Via Chartmill
US Futures Tumble As Traders Await Trump's Congress Address: 'Volatility Is Certainly Being Fed By Trump 2.0 Moves,' Says Expert
U.S. stock futures declined on Tuesday following the worst trading day of 2025 on Monday. Futures fell in premarket trading except Nasdaq 100. 
Via Benzinga
Topics Economy Government
Exposures Interest Rates Political
Get insights into the top gainers and losers of Monday's after-hours session.
Discover the top movers in Monday's after-hours session and stay informed about the post-market dynamics. 
Via Chartmill
Biodesix Announces Fourth Quarter and Fiscal Year 2024 Results
From Biodesix, Inc.
Via GlobeNewswire
Earnings Scheduled For March 3, 2025
Via Benzinga
Biodesix to Present at TD Cowen 45th Annual Health Care Conference
From Biodesix, Inc.
Via GlobeNewswire
Biodesix to Report Fourth Quarter and Full Year 2024 Financial Results on March 3, 2025
From Biodesix, Inc.
Via GlobeNewswire
12 Health Care Stocks Moving In Friday's Pre-Market Session
Via Benzinga
Biodesix Announces Preliminary Fourth Quarter and Full-Year 2024 Results (Unaudited)
Grew full-year revenue to an estimated $71.3 million, an increase of 45% 
From Biodesix, Inc.
Via GlobeNewswire
Biodesix Announces Publication of a New Nodify CDT® Clinical Validation Study
Analysis of 447 patients receiving the Nodify CDT blood-based lung nodule test published in CHEST Pulmonary Journal reaffirms test performance 
From Biodesix, Inc.
Via GlobeNewswire
Biodesix Announces Third Quarter 2024 Results and Highlights
From Biodesix, Inc.
Via GlobeNewswire
Biodesix to Participate in Three Investor Conferences in November
From Biodesix, Inc.
Via GlobeNewswire
Biodesix to Report Third Quarter 2024 Financial Results on November 1, 2024
From Biodesix, Inc.
Via Business Wire
Biodesix Announces New Data Presentation at CHEST 2024 Annual Meeting and the Launch of a Complementary Clinical Study
From Biodesix, Inc.
Via Business Wire
12 Health Care Stocks Moving In Friday's Pre-Market Session
Via Benzinga
Why Phoenix Motor Shares Are Trading Higher By 150%; Here Are 20 Stocks Moving Premarket
Via Benzinga
Biodesix to Present at Two Investor Conferences in September
From Biodesix, Inc.
Via Business Wire
BDSX Stock Earnings: Biodesix Beats EPS, Beats Revenue for Q2 2024
BDSX stock results show that Biodesix beat analyst estimates for earnings per share and beat on revenue for the second quarter of 2024. 
Via InvestorPlace
Biodesix Announces Second Quarter 2024 Results and Highlights
From Biodesix, Inc.
Via Business Wire
Biodesix to Present at Canaccord Genuity’s 44th Annual Growth Conference
From Biodesix, Inc.
Via Business Wire
Biodesix to Report Second Quarter 2024 Financial Results on August 7, 2024
From Biodesix, Inc.
Via Business Wire
Biodesix Named to Inc. Magazine’s 2024 “Best Workplaces”
From Biodesix, Inc.
Via Business Wire
Biodesix to Participate in Two Investor Conferences in June
From Biodesix, Inc.
Via Business Wire
Biodesix to Present New Data on the Nodify XL2® Test at ATS 2024 Annual Meeting
From Biodesix, Inc.
Via Business Wire
BDSX Stock Earnings: Biodesix Beats EPS, Beats Revenue for Q1 2024
BDSX stock results show that Biodesix beat analyst estimates for earnings per share and beat on revenue for the first quarter of 2024. 
Via InvestorPlace
Biodesix Announces First Quarter 2024 Results Driven by Growth in Lung Diagnostic Testing for Lung Nodule Management
From Biodesix, Inc.
Via Business Wire
Biodesix to Participate in the 2024 RBCCM Global Healthcare Conference
From Biodesix, Inc.
Via Business Wire
< Previous 1 2 3 4 5 6 7 8 9 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.